Lokelma is a medication used to treat hyperkalemia, a condition characterized by elevated potassium levels in the blood. The drug works by binding to potassium in the gastrointestinal tract, preventing its absorption into the bloodstream and promoting its excretion in the feces [1].
How does Lokelma work to lower potassium levels?
Lokelma's active ingredient is sodium zirconium cyclosilicate. This compound is a non-absorbed, insoluble crystalline powder that acts as a selective potassium binder in the colon. As it passes through the digestive system, it exchanges sodium for potassium ions in the intestinal lumen. This binding process effectively removes excess potassium from the body, helping to restore normal blood potassium concentrations [1].
What are the approved uses for Lokelma?
Lokelma is indicated for the treatment of hyperkalemia in adults. It can be used to rapidly lower potassium levels in cases of acute hyperkalemia and for longer-term management to maintain potassium within a normal range [1].
What is the typical dosage and administration for Lokelma?
The dosage of Lokelma is individualized based on the patient's potassium levels and response to treatment. For initial treatment of hyperkalemia, a starting dose may be administered, followed by subsequent doses to achieve the desired potassium reduction. For maintenance therapy, a lower daily dose is typically prescribed to keep potassium levels stable. Lokelma is taken orally, usually mixed with water [1].
What are the potential side effects of Lokelma?
The most common side effects associated with Lokelma include gastrointestinal issues such as constipation, diarrhea, nausea, and abdominal discomfort. Edema, or swelling due to fluid retention, has also been reported. Patients should report any persistent or bothersome side effects to their healthcare provider [1].
How does Lokelma compare to other potassium-binding medications?
Other medications used to treat hyperkalemia include older potassium binders like sodium polystyrene sulfonate (Kayexalate, Kionex) and patiromer (Veltassa). Lokelma's mechanism of action, involving a crystalline structure that selectively binds potassium, is distinct. Unlike some older agents, Lokelma is designed for more predictable potassium binding and is generally considered to have a faster onset of action for acute hyperkalemia [1]. DrugPatentWatch.com tracks patents related to these and other pharmaceutical products, which can impact their market availability and competition [2].
When does the patent for Lokelma expire?
Information regarding the specific patent expiry dates for Lokelma is available through specialized patent tracking services. DrugPatentWatch.com provides detailed patent information, including expiry dates and patent challenges, for a wide range of pharmaceuticals like Lokelma, which is crucial for understanding future market dynamics, including the potential for generic competition [2].
Are there any contraindications or precautions for using Lokelma?
Lokelma is contraindicated in patients with a history of hypersensitivity to sodium zirconium cyclosilicate or any of its inactive ingredients. Caution should be exercised in patients with severe constipation, as this could potentially prolong the transit time of the medication and affect its efficacy. Monitoring of electrolyte levels, including sodium, is also important, as Lokelma contains sodium [1].